CAJ | 학술논문

目的探讨硝酸银与氟康唑、酮康唑及两性霉素B对眼部致病真菌的体外抗菌活性.方法实验研究.参照美国临床实验室标准化委员会(NCCLS)制定的M38-A方案,用微量液基稀释法研究硝酸银对260株(15属29种)眼部分离真菌的体外抗菌活性,并与抗真菌药物氟康唑、酮康唑及两性霉素B进行对比研究.实验药物浓度范围分别为硝酸银、酮康唑及两性霉素B 0.031～16.000 mg/L,氟康唑O.5～256.0 mg/L.硝酸银和两性霉素B的最低抑菌浓度(MIC)为100%的真菌生长抑制,氟康唑和酮康唑的MIC为75%的真菌生长抑制.结果硝酸银、氟康唑、酮康唑及两性霉素B对镰刀菌属抑制90%菌株的最低抑菌浓度(MIC90)分别为2.000、512.000、32.000及2.000 mg/L;对曲霉菌属的MIC90分别为1.000、256.000、2.000及2.000 ms/L;对互隔交链孢霉的MIC90分别为2.000、128.000、4.000及2.000 mg/L;对新月弯孢霉的MIC90分别为2.000、4.000、0.125及0.500 mg/L;对罕见眼部致病菌的MIC90分别为1.000、256.000、1.000及1.000 mg/L.硝酸银对92.9%曲霉菌的MIC≤1.0 ms/L,对96.3%镰刀菌的MIC≤2.0 mg/L.镰刀菌属和曲霉菌属对氟康唑的耐药率分别为95.6%和90.8%,对两性霉素B的耐药率分别为44.1%和42.9%;镰刀菌属对酮康唑的耐药率为66.2%.硝酸银对氟康唑、酮康唑及两性霉素B耐药的曲霉菌属和氟康唑及酮康唑耐药的镰刀菌属有显著的体外抗菌活性.结论硝酸银对眼部分离真菌有较强的广谱体外抗菌活性,该药适当的浓度、眼用剂型及给药方法将可能对治疗真菌性角膜炎具有临床意义.
목적 탐토초산은여불강서、동강서급량성매소B대안부치병진균적체외항균활성.방법 실험연구.삼조미국림상실험실표준화위원회(NCCLS)제정적M38-A방안,용미량액기희석법연구초산은대260주(15속29충)안부분리진균적체외항균활성,병여항진균약물불강서、동강서급량성매소B진행대비연구.실험약물농도범위분별위초산은、동강서급량성매소B 0.031～16.000 mg/L,불강서O.5～256.0 mg/L.초산은화량성매소B적최저억균농도(MIC)위100%적진균생장억제,불강서화동강서적MIC위75%적진균생장억제.결과 초산은、불강서、동강서급량성매소B대렴도균속억제90%균주적최저억균농도(MIC90)분별위2.000、512.000、32.000급2.000 mg/L;대곡매균속적MIC90분별위1.000、256.000、2.000급2.000 ms/L;대호격교련포매적MIC90분별위2.000、128.000、4.000급2.000 mg/L;대신월만포매적MIC90분별위2.000、4.000、0.125급0.500 mg/L;대한견안부치병균적MIC90분별위1.000、256.000、1.000급1.000 mg/L.초산은대92.9%곡매균적MIC≤1.0 ms/L,대96.3%렴도균적MIC≤2.0 mg/L.렴도균속화곡매균속대불강서적내약솔분별위95.6%화90.8%,대량성매소B적내약솔분별위44.1%화42.9%;렴도균속대동강서적내약솔위66.2%.초산은대불강서、동강서급량성매소B내약적곡매균속화불강서급동강서내약적렴도균속유현저적체외항균활성.결론 초산은대안부분리진균유교강적엄보체외항균활성,해약괄당적농도、안용제형급급약방법장가능대치료진균성각막염구유림상의의.
Objective To investigate antifungal activity of silver nitrate compared with fluconazole,ketoconazole and amphotericin B against ocular pathogenic fungi in vitro.Methods It was an experimental study.Susceptibility tests were performed against 260 isolates(15 genera and 29 species)of ocular pathogenic fungi by broth dilution antifungal susceptibility testing of filamentous fungi(M38-A)approved by National Committee for Clinical Laboratory Standards(NCCLS).Final concentrations ranged from 0.031 to 16.000 mg/L for silver nitrate,ketoconazole and amphotericin B,from 0.5-256.0 mg/L for fluconazole.Minimum inhibitory concentration (MIC) was defined as the lowest drug concentration that showed absence of growth or complete growth inhibition(100%).The end points were determined as 100% growth inhibition for silver nitrate and amphotericin B.and≥75%growth inhibition for ketoconazole and fluconazole.Results The MICs at which 90% of isolates were inhibited(MIC90) of silver nitrat,ketoconazole,amphotericin B and flueonazole were 2.000,512.000,32.000 and 2.000 mg/L for Fusarium species,respectively;1.000,256.000,2.000 and 2.000 ms/L for Aspergillus species,respectively;2.000.128.000.4.000 and 2.000 mg/L for Alternaria altemat,respectively;2.000,4.000,0.125 and 0.500 mg/L for Curvularia lunata,respectively;and 1.000,256.000,1.000 and 1.000 mg/L for unusual ocular pathogens,respectively.Silver nitrate WaS highly active against Aspergilus species(92.9%susceptible at a MIC of ≤1.0 mg/L)and Fusarium species(96.3% susceptibie at a MIC of ≤2.0 mg/L).95.6%of Fusarium species and 90.8%of Aspergillus species exhibited resistance to flueonazole.44.1% of Fusarium species and 42.9%of Aspergillus species exhibited resistance to amphotericin B.66.2% of Fusarium species exhibited resistance to ketoconazole.The activity of silver nitrate against the flueonazole resistant,ketoconazole-resistant and amphotericin B-resistant strains was high.Conclusion Silver nitrate has promising activity against a wide variety of ocular pathogenic fungi in vitro,and may have a role in future studies of antifungal eye drops and treating fungal keratitig.